Abstract

Introduction: Anticoagulants including warfarin and novel oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (NVAF) patients. Limited data are available on real-world use of warfarin and NOACs in these patients since the entry of NOACs into the US market in October, 2010. Hypothesis: Warfarin and NOACs are prescribed for stroke prevention differentially based on patient characteristics. Methods: Incident cases of NVAF were identified from GE electronic medical records database between 11/2010 and 08/2011 based on ICD-9 codes 427.31 and 427.32. Baseline characteristics were obtained from medical record history prior to diagnosis. Patients were assessed over 6 months for initiation of warfarin or NOAC (dabigatran or rivaroxaban). Factors associated with anticoagulant initiation and NOAC initiation were examined using multivariate logistic regression analyses. Results: Among 19,730 NVAF patients, mean age was 70.8 years, 45.5% were female, and 36.5% initiated an anticoagulant (31.0% warfarin and 5.5% NOAC). CHADS2 score differed across treatment groups with CHADS2 ≥2 found in 47.9%, 45.6% and 36.3% of patients receiving warfarin, NOACs, and no anticoagulants, respectively (p < 0.001). Age, prescriber type, hypertension, diabetes, CHF, prior stroke/TIA, prior MI, and history of GI or other bleeding were significantly associated with the use of anticoagulants. NOAC use was more likely than warfarin in patients with hypertension (OR=1.19), history of GI bleeding (OR=1.40) and prior aspirin use (OR=1.81) but less likely in those with history of CHF (OR=0.70). Conclusions: Since the entry of NOACs, over 60% of newly diagnosed NVAF patients did not receive anticoagulants despite 36% of those patients having CHADS2 score ≥2. GI bleeding history, CHF, and prior aspirin use were major clinical factors associated with NOAC use. Further research is warranted to examine changes in anticoagulant treatment over time.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.